A1c Reduction + CV Protection The REWIND trial demonstrated that Trulicity reduced major adverse cardiovascular events (MACE) by 12% (HR 0.88) in adults with type 2 diabetes who had established cardiovascular disease or multiple cardiovascular risk factors-across a median follow-up of 5.4 years
For years, the options have been frustratingly limited: rest, physical therapy that feels endless, injections that offer temporary relief, and surgery as a daunting last resort
A head-to-head comparison in Cardiovascular Diabetology Endocrinology Reports also compiled these directly from both trials
Using a new sterile syringe for every draw, cleaning the stopper with alcohol before each puncture, and never drawing from a vial while sick or working in a non-clean environment are the practical controls
I feel balanced, lighter, and so much more in control of my day and my snacking